Cognitive Behavioral Therapy Reduces Benzodiazepine Anxiolytics Use in Japanese Patients with Mood and Anxiety Disorders: A Retrospective Observational Study

References

• Lader M. Benzodiazepines revisited–will we ever learn? Addiction. 2011;106(12):2086–2109.21714826
   PubMed Web of Science ®Google Scholar
• Martin JL, Sainz-Pardo M, Furukawa TA, Martin-Sanchez E, Seoane T, Galan C. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol. 2007;21(7):774–782. doi:10.1177/026988110707735517881433
   PubMed Web of Science ®Google Scholar
• van Balkom AJ, Bakker A, Spinhoven P, Blaauw BM, Smeenk S, Ruesink B. A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis. 1997;185(8):510–516. doi:10.1097/00005053-199708000-000069284865
   PubMed Web of Science ®Google Scholar
• Holbrook A, Crowther R, Lotter A, Endeshaw Y. The role of benzodiazepines in the treatment of insomnia: meta-analysis of benzodiazepine use in the treatment of insomnia. J Am Geriatr Soc. 2001;49(6):824–826. doi:10.1046/j.1532-5415.2001.49161.x11454123
   PubMed Web of Science ®Google Scholar
• Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004;18(1):37–48. doi:10.2165/00023210-200418010-0000414731058
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Short- and Long-Term Use of Benzodiazepines in Patients with Generalized Anxiety Disorder: A Review of Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014.
   Google Scholar
• Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder, third edition. Am Psychiatry Assoc. 2010;152.
   Google Scholar
• Dold M, Bartova L, Mendlewicz J. Clinical correlates of augmentation/combination treatment strategies in major depressive disorder. Acta Psychiatr Scand. 2018;137(5):401–412. doi:10.1111/acps.1287029492960
   PubMed Web of Science ®Google Scholar
• International Narcotics Control Board. Report of the International Narcotics Control Board on the Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes. New York: International Narcotics Control Board, United Nations; 2011.
   Google Scholar
• Nakagawa A, Williams A, Sado M, et al. Comparison of treatment selections by Japanese and US psychiatrists for major depressive disorder: A case vignette study. Psychiatry Clin Neurosci. 2015;69(9):553–562. doi:10.1111/pcn.1227325601043
   PubMed Web of Science ®Google Scholar
• Michelini S, Cassano GB, Frare F, Perugi G. Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders. Pharmacopsychiatry. 1996;29(4):127–134. doi:10.1055/s-2007-9795588858711
   PubMed Web of Science ®Google Scholar
• Salzman C. Benzodiazepine treatment of panic and agoraphobic symptoms: use, dependence, toxicity, abuse. J Psychiatr Res. 1993;27(Suppl 1):97–110. doi:10.1016/0022-3956(93)90021-S7908335
   PubMed Web of Science ®Google Scholar
• Mellman TA, Uhde TW. Withdrawal syndrome with gradual tapering of alprazolam. Am J Psychiatry. 1986;143(11):1464–1466.3535544
   PubMed Web of Science ®Google Scholar
• Pecknold JC, Swinson RP, Kuch K, Lewis CP. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects. Arch Gen Psychiatry. 1988;45(5):429–436. doi:10.1001/archpsyc.1988.018002900430063282479
   PubMed Web of Science ®Google Scholar
• Schweizer E, Rickels K, Case WG, Greenblatt DJ. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Arch Gen Psychiatry. 1991;48(5):448–452. doi:10.1001/archpsyc.1991.018102900600122021297
   PubMed Web of Science ®Google Scholar
• Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev. 2006;26(1):17–31. doi:10.1016/j.cpr.2005.07.00316199119
   PubMed Web of Science ®Google Scholar
• Gosselin P, Ladouceur R, Morin CM, Dugas MJ, Baillargeon L. Benzodiazepine discontinuation among adults with GAD: a randomized trial of cognitive-behavioral therapy. J Consult Clin Psychol. 2006;74(5):908–919. doi:10.1037/0022-006X.74.5.90817032095
   PubMed Web of Science ®Google Scholar
• Otto MW, McHugh RK, Simon NM, Farach FJ, Worthington JJ, Pollack MH. Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: further evaluation. Behav Res Ther. 2010;48(8):720–727. doi:10.1016/j.brat.2010.04.00220546699
   PubMed Web of Science ®Google Scholar
• World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization; 1992.
   Google Scholar
• McKay D, Sookman D, Neziroglu F, et al. Accreditation Task Force of The Canadian Institute for Obsessive Compulsive Disorders. Efficacy of cognitive-behavioral therapy for obsessive-compulsive disorder. Psychiatry Res. 2015;225(3):236–246. doi:10.1016/j.psychres.2014.11.05825613661
   PubMed Web of Science ®Google Scholar
• Resick PA, Monson CM, Chard KM. Cognitive Processing Therapy for PTSD: A Comprehensive Manual. The Guildford Press; 2016.
   Google Scholar
• Barlow DH, Farchione TJ, Bullis JR, et al. The unified protocol for transdiagnostic treatment of emotional disorders compared with diagnosis-specific protocols for anxiety disorders: a randomized clinical trial. JAMA Psychiatry. 2017;74(9):875–884. doi:10.1001/jamapsychiatry.2017.216428768327
   PubMed Web of Science ®Google Scholar
• Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci. 2015;69(8):440–447. doi:10.1111/pcn.1227525601291
   PubMed Web of Science ®Google Scholar
• Leucht S, Samara M, Heres S, Davis JM. Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull. 2016;42(Suppl 1):S90–4. doi:10.1093/schbul/sbv16727460622
   PubMed Web of Science ®Google Scholar
• Paul-Christian B. brms: an R package for bayesian multilevel models using stan. J Stat Softw. 2017;80(1):1–28.
   Web of Science ®Google Scholar
• Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults; a clinical practice guideline from the American college of physicians. Ann Intern Med. 2016;165:125–133. doi:10.7326/M15-217527136449
   PubMed Web of Science ®Google Scholar
• Otto MW, Hong JJ, Safren SA. Benzodiazepine discontinuation difficulties in panic disorder conceptual model and outcome for cognitive-behavior therapy. Curr Pharm Des. 2002;8(1):75–80. doi:10.2174/138161202339672611812251
   PubMed Web of Science ®Google Scholar
• Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14:S1. doi:10.1186/1471-244X-14-S1-S125081580
   PubMed Web of Science ®Google Scholar